SCHEMBL23945307

SCHEMBL23945307

CCNCCOCCOCCNC(=O)NCC(C)C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 2/20 0.50
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
CYP2D6 P10635 1/20 0.37
CYP2C19 P33261 1/20 0.37
MAPT P10636 2/20 0.36
EPHX2 P34913 3/20 0.35
HSD17B10 Q99714 2/20 0.35
TSHR P16473 1/20 0.34
ALDH1A1 P00352 1/20 0.33
KDM4E B2RXH2 1/20 0.33
TP53 P04637 1/20 0.33
SCN1A P35498 1/20 0.33
SCN2A Q99250 1/20 0.33
SCN3A Q9NY46 1/20 0.33
MMP1 P03956 1/20 0.33
MMP8 P22894 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
HPGD P15428 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22837658 0.90 EPHX1 (0.49) EPHX1MEN1KMT2ACYP2D6CYP2C19
SCHEMBL24765447 0.89 EPHX1 (0.53) EPHX1MEN1KMT2ACYP2D6CYP2C19
SCHEMBL23806970 0.87 MEN1 (0.46) EPHX1MEN1KMT2ACYP2D6CYP2C19
SCHEMBL25700630 0.86 EPHX1 (0.45) EPHX1MEN1KMT2ACYP2D6CYP2C19
SCHEMBL6290266 0.84 MEN1 (0.44) EPHX1MEN1KMT2AEPHX2SMN1; SMN2
SCHEMBL23695977 0.84 EPHX1 (0.50) EPHX1MEN1KMT2ACYP2D6CYP2C19
SCHEMBL24673081 0.83 EPHX1 (0.49) EPHX1MEN1KMT2ACYP2D6CYP2C19
SCHEMBL25922601 0.83 EPHX1 (0.43) EPHX1MEN1KMT2ACYP2D6CYP2C19
SCHEMBL22861950 0.83 EPHX1 (0.46) EPHX1MEN1KMT2AEPHX2ALDH1A1
SCHEMBL6290261 0.83 MEN1 (0.41) EPHX1MEN1KMT2AMAPTEPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240025878-A1 MDM2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-01-25 US disclosed
US-20230398223-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-12-14 US disclosed
EP-4194457-A1 COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF Shanghai Leadingtac Pharmaceutical Co., Ltd. (CN) 2023-06-14 EP disclosed
US-20220340570-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2022-10-27 US disclosed
US-11352350-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2022-06-07 US disclosed
US-20210323952-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2021-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240025878-A1 MDM2 DEGRADERS AND USES THEREOF MDM2, TP53, MDM4 EPHX1 2320/4885MEN1 2268/4885KMT2A 1193/4885
US-11352350-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 EPHX1 1684/4885MEN1 4055/4885KMT2A 445/4885
US-20210323952-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 EPHX1 1684/4885MEN1 4055/4885KMT2A 445/4885
US-20220340570-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 EPHX1 1684/4885MEN1 4055/4885KMT2A 445/4885
US-20230398223-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 EPHX1 1684/4885MEN1 4055/4885KMT2A 445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.